Targeting RNA with small molecules offers a new chemical space for drug discovery, with the exciting potential to overcome limitations of current drug classes such as poor bioavailability, toxicity and resistance. 

There is an electrifying sense of anticipation with a plethora of new companies emerging to develop RNA targeting small molecules to treat oncology, neurology and beyond.  

The momentum of this groundbreaking approach, underscoring its potential to revolutionize the lives of millions, is reaching a pivotal point as the field witnesses a spectacular surge in RNA degraders, inhibitors, modulators and binders. 

With this, the 6th RNA Targeted Drug Discovery & Development Summit returns as the leading industry forum singularly focused on uniting and empowering this community once again. Here, experts delve into cutting-edge frontiers of early discovery, pre-clinical and translation with the shared objective of developing first-in-class RNA targeting small molecules.